Pembrolizumab

證據等級: L5

預測適應症: 10 個

Pembrolizumab: From Unspecified Original Indication to Gingival Fibromatosis

One-Sentence Summary

Pembrolizumab (DrugBank DB09037) is an anti-PD-1 immune checkpoint inhibitor; its original approved indication is not recorded in this evidence pack, and detailed mechanism-of-action data is also missing. The TxGNN model’s top-ranked candidate for repurposing is Gingival Fibromatosis, with a prediction score of 99.40%, but this candidate currently has 0 clinical trials and 0 publications supporting it, and the evidence pack’s own mechanistic review found no biological link between PD-1/PD-L1 blockade and this benign condition.

Quick Overview

Item	Content
Original Indication	Not available — no original indication or product licence data on file
Predicted New Indication	Gingival Fibromatosis (fibromatosis, gingival)
TxGNN Prediction Score	99.40%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available for pembrolizumab in this evidence pack. Based on the literature captured elsewhere in this pack, pembrolizumab is known to act as a monoclonal antibody that blocks the PD-1 receptor, restoring T-cell-mediated anti-tumour immunity in malignancies with immune evasion (e.g. non-small-cell lung cancer, melanoma).

Gingival fibromatosis, however, is a benign, non-immunogenic overgrowth of gingival fibrous connective tissue, typically driven by hereditary fibrotic pathways rather than tumour-immune evasion. The evidence pack’s own mechanistic assessment explicitly states there is no known association between PD-1/PD-L1 checkpoint blockade and this condition.

This candidate therefore represents a case where the TxGNN model assigned a high similarity score, but neither the underlying biology nor any external evidence currently supports the prediction. It should be treated as a model-generated hypothesis only, not as a validated repurposing signal.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Cytotoxicity

Pembrolizumab is an antineoplastic agent (immune checkpoint inhibitor), as evidenced by the drug-review and oncology trial literature captured elsewhere in this evidence pack (e.g. PMID 27398650, “Pembrolizumab (Keytruda)”).

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 checkpoint inhibitor)
Myelosuppression Risk	Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Please refer to the Product Information (PI) warnings and precautions
Monitoring Items	Please refer to the Product Information (PI) warnings and precautions
Handling Protection	Please refer to the Product Information (PI) warnings and precautions

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked candidate (Gingival Fibromatosis) has no clinical trial or literature support, and the evidence pack’s own mechanistic analysis finds no biological rationale for immune checkpoint blockade in this benign, non-immunogenic condition. Pembrolizumab is also not currently marketed in this jurisdiction, and a blocking data gap on local product-label warnings/contraindications (DG001) prevents any safety-tier assessment. Note: all 10 TxGNN-ranked candidates in this evidence pack (including anatomically plausible ones such as lung hilum carcinoma and pulmonary sulcus neoplasm) were independently scored “Hold” — none currently clear an evidence threshold beyond model prediction alone.

To proceed, the following is needed:

Local product-label warnings and contraindications (DG001, Blocking) — required before any S1 safety review can begin
Verified mechanism-of-action data from DrugBank (DG002)
Original approved indication(s) and regulatory history for pembrolizumab
If pursuing repurposing further, prioritise candidates with class-level mechanistic plausibility and disease-specific evidence (e.g. lung hilum carcinoma, lung germ cell tumour) over candidates like gingival fibromatosis that lack any supporting rationale
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.